Freshfields advises BioNTech on entering into worldwide strategic collaboration with Genentech to develop individualised mRNA cancer therapies
Freshfields has advised BioNTech AG on a strategic partnership with Genentech, a member of the Roche Group
Freshfields Bruckhaus Deringer LLP (Freshfields), has advised BioNTech AG, a fully integrated, private biotechnology company that develops personalised cancer immunotherapies, on a global, strategic partnership with Genentech, a member of the Roche Group. Together the firms will develop, manufacture and market personalised messenger RNA (mRNA)-based cancer vaccines.